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Using reverse genetics methods, we constructed three different transfectant influenza A viruses encoding an Ld-restricted,
nine amino-acid-long fragment, corresponding to amino-acid residues 876–884, of b-galactosidase (b-gal). Sequences
encoding this epitope were nested within the hemagglutinin (HA) or neuraminidase (NA) open reading frames. Alternatively,
an independent b-gal mini-gene, preceded by an endoplasmic reticulum insertion signal sequence, was placed in a bicistronic
arrangement in the NA RNA segment of the virus. All three transfectants mediated the presentation of the epitope to a
b-gal-specific CTL clone. Furthermore, each of the three transfectant viruses expressing the b-gal fragment elicited specific
cytolytic responses in vivo. Most importantly, these H1N1 transfectants mediated the regression of established murine
pulmonary metastases. Tumor regression in mice was also achieved in the presence of preexisting immunity against an
H3N2 influenza A virus serotype. Nononcogenic and nonintegrating, transfectant influenza A viruses are attractive candi-
dates for development as antitumor vaccines. © 1998 Academic Press
INTRODUCTION
There is strong evidence suggesting that the stimula-
tion of a potent and specific immune response against
tumor cells will result in tumor clearance. Data from mice
and human suggest that T lymphocytes are an important
element of that response, and the antigens recognized
by T cells have, in some cases, been identified (Green-
berg, 1991; Kawakami and Rosenberg, 1997). While can-
cer cells may express proteins designated tumor-asso-
ciated antigens (TAA), growing cancers generally do not
elicit TAA-specific immune responses that are capable of
mediating their rejection. Attempts to increase the poor
immunogenicity of tumor cells have included physical
modification of the tumor cells (including g-irradiation),
the inoculation of mixtures of tumor cells and pathogens
(viruses, bacteria, and bacterial extracts), and more re-
cently, gene-modification of the tumor cells with a variety
of immunomodulatory molecules.
In contrast to tumor cells, most viruses are powerful
inducers of cellular immune responses. An entirely
new and potentially more effective strategy for eliciting
immune responses against TAA involves the insertion
of the recently cloned genes encoding TAA into recom-
binant viruses (reviewed in (Restifo, 1996)). These re-
combinant viruses are then used as therapeutic vac-
cines to induce immune responses against tumor
cells. A number of recombinant expression vectors
have been shown to be useful in the prevention and, in
some cases, the treatment of tumors in experimental
animals including poxviruses [vaccinia (Moss, 1996;
Bronte et al., 1997), MVA (Carroll et al., 1997), fowlpox
(Wang et al., 1995), and canary pox (Kawakita et al.,
1997)], adenoviruses (Randrianarison-Jewtoukoff and
Perricaudet, 1995; Chen et al., 1996), polioviruses (An-
dino et al., 1994; Ansardi et al., 1994), and nonviral
vectors including plasmid DNA administered by injec-
tion and by ‘‘gene gun’’ (Irvine et al., 1996).
Despite the potential application of these vectors to
the treatment of patients with cancer, the reasons for the
continued exploration of new vectors are threefold. First,
although important properties of anticancer vectors can
be deduced (e.g., safety, efficacy, ease of engineering,
genetic stability and the lack of oncogenicity, integration,
and immunosuppression), therapeutic efficacy in the
clinic has yet to be demonstrated with any of the vectors
now available. Second, preexisting immune responses in
cancer patients to some of the vectors listed above can
hinder their function as recombinant immunogens. For
example, neutralizing antibodies can be present in the
patients as a result of previous infection with a wild-type
form of the vector (e.g., adenovirus) or as a result of prior
immunization (e.g., vaccinia virus or poliovirus). Third, the
availability of a number of vectors makes novel prime/
boosting protocols possible (Rodrigues et al., 1994; Mu-
rata et al., 1996). Prime-boost combinations employing
non-cross-reactive vectors can be much more effective
than combinations that employ repeated doses of a sin-
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gle vector, perhaps due to the presence of vector-
specific antibodies following the first immunization.
In this report, we explore the potential of transfectant
influenza A virus vectors for use in the immunotherapy of
cancer. The genetic manipulation of influenza viruses is
now possible, and we have developed reverse genetics
techniques that allow us to generate stable recombinant
(transfectant) viruses expressing foreign epitopes and/or
polypeptides (Palese et al., 1996). Influenza A viruses are
strong inducers of cellular immune responses. Strikingly,
mice immunized with an influenza virus vector and
boosted with a vaccinia virus vector expressing the
same antigen are able to generate specific cytolytic
CD81 T lymphocytes against the expressed antigen that
represent approximately 1% of the total splenic CD81
cells (Murata et al., 1996). Influenza A viruses are non-
integrating, nononcogenic viruses. There are a number
of nontransmissible attenuated strains of influenza vi-
ruses available that could be used in humans (Chanock
and Murphy, 1980; Maassab et al., 1988). Since influenza
viruses change their antigenic determinants very quickly,
one could also choose among different viral strains to
avoid the presence of preexisting immunity against the
virus in patients.
We have tested the efficacy of transfectant influenza
viruses expressing a TAA to clear tumors in a murine
cancer model. The tumor used in our studies is the
experimental murine tumor CT26, which has been trans-
fected with the lacZ gene [which encodes b-gal, used in
this system as a model TAA (Wang et al., 1995)]. We
engineered transfectant influenza viruses expressing a
CTL epitope from b-gal, then determined the ability of
these viruses to induce a therapeutic cellular immune
response in mice bearing experimental tumors.
RESULTS
Rescue of transfectant influenza A viruses encoding a
T cell epitope from b-galactosidase
Recombinant viruses encoding CD81 T cell antigenic
determinants derived from cancer cells might mediate
the regression of tumors in vivo (Irvine et al., 1995;
McCabe et al., 1995; Restifo, 1996). We thus constructed
transfectant influenza A viruses encoding TPHPARIGL,
which corresponds to amino acids 876–884 in the intact
b-gal protein. This determinant is presented by the MHC
class I Ld-molecule on the surface of our experimental
tumor, CT26.CL25 (Gavin et al., 1993; Wang et al., 1995).
Three different influenza A virus transfectants were
generated (Fig. 1). The first transfectant virus, called
MINIGAL, contains a minigene in a bicistronic arrange-
ment within the NA-specific viral RNA segment. mRNA
derived from this segment uses a mammalian internal
ribosomal entry site (IRES) placed downstream of the
minigene and upstream of the NA gene to achieve trans-
lation of the NA protein. The minigene is translated
following the usual cap-dependent initiation of transla-
tion in eukaryotic cells. In this transfectant virus, the
minigene was engineered to encode the E3/19K leader
sequence at the N terminus of the b-gal epitope TPH-
PARIGL. The ER-insertion signal sequence has been
found, in some cases, to greatly augment the immuno-
genicity of the encoded epitope (Restifo et al., 1995). The
control virus for this construct, designated BIP-NA virus,
employs the same IRES element upstream of the NA
open reading frame but does not contain the b-gal
epitope minigene (Garcı´a-Sastre et al., 1994). The sec-
ond virus, NAGAL, encodes the amino-acid sequence
TPHPARIGL inserted in the stalk region of the NA protein.
The control for this construct is the MNA transfectant
FIG. 1. Schematic representation of the recombinant genes of the transfectant influenza viruses expressing the CD81 T-cell b-gal epitope
TPHPARIGL. (A) MINIGAL recombinant gene. The b-gal epitope is expressed downstream of a leader peptide (characters in italics) as an independent
polypeptide from a bicistronic NA gene. Expression of the viral NA protein in this gene is achieved via internal initiation of translation mediated by
an IRES element derived from the BiP mRNA (Garcı´a-Sastre et al., 1994). (B) NAGAL. The b-gal epitope is expressed as part of the amino acid
sequence of the NA protein. (C) BHAGAL. The b-gal epitope is expressed as part of the amino acid sequence of the HA protein. The NA and HA open
reading frames (ORF) are indicated. Black boxes represent noncoding regions in the represented genes.
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virus, which contains the irrelevant peptide SYVPSAEQI
inserted into the NA stalk. This sequence is derived from
the CS protein of Plasmodium yoelii (Rodrigues et al.,
1994). The third virus, called BHAGAL, encodes the b-gal
epitope inserted into the antigenic site B of the HA
protein. The control for this virus, designated ELDKWAS,
contains the gp41 HIV-derived sequence ELDKWAS in-
serted into the same domain of the HA (Muster et al.,
1995).
Transfectant viruses MINIGAL, NAGAL, and BHAGAL
were rescued following RNP transfections into helper
influenza virus-infected cells. Sequence analysis of the
rescued viruses confirmed the presence of the foreign
b-gal-derived sequences. Viral titers obtained in MDBK
cells for the transfectant viruses expressing the b-gal-
epitope were comparable to the control transfectant vi-
ruses BIP-NA, MNA and ELDKWAS and approximately 1
log lower than wild-type influenza A/WSN/33 virus.
Transfectant influenza virus-infected cells specifically
present the b-gal-epitope to CD81 T cells
To ascertain if the b-gal-epitope expressed by the
transfectant influenza viruses could be processed and
presented in the context of MHC class I molecules,
CT26.WT tumor cells were infected with the different
transfectant influenza A viruses encoding the b-gal
epitope TPHPARIGL or the control viruses. Infected cells
were then co-incubated for 24 h with a CD81 T lympho-
cyte clone specific for this epitope. Supernatants were
then assayed for GM–CSF, and the results are shown in
Fig. 2. Cells that were infected with MINIGAL, NAGAL,
and BHAGAL viruses elicited specific release of GM–
CSF. Neither control transfectant virus- or wild-type virus-
infected cells were recognized by the b-gal-specific
CTLs. Thus the transfectant influenza A viruses were
found to mediate the expression of the Ld-restricted
b-gal epitope in forms that could be processed and
presented at the surface of infected cells.
Transfectant influenza A viruses elicit a b-gal specific
cytolytic response in mice
Cytolytic responses mediated by CD81 T lymphocytes
specific for TAA play an important role in the regression of
established tumors in both mice and humans (Greenberg,
1991; Rao et al., 1996; Rosenberg, 1997). To evaluate the
function of transfectant influenza A viruses in the priming of
b-gal-specific cytotoxic responses in vivo, we immunized
mice with the panel of influenza A viruses. Three weeks
later, splenocytes from immunized mice were cultured in
the presence of the Ld-restricted b-gal876-884 peptide for 6
days and subsequently tested in a microcytotoxicity assay.
Cultured splenocytes from mice immunized with the three
transfectant influenza A viruses expressing the b-gal
epitope (MINIGAL, NAGAL, and BHAGAL viruses) were
capable of specific recognition of CT26.CL25 cells or of
CT26.WT cells pulsed with synthetic peptide (Fig. 3). No
specific recognition was elicited by wild-type virus or by the
control transfectant viruses.
Treatment of 3-day-old established tumors by
vaccination with transfectant influenza A viruses
Specific cytolytic responses were elicited in mice by
the transfectant influenza A viruses expressing the
b-gal876-884 peptide. To evaluate whether these re-
sponses had any impact on the growth of tumor cells, we
immunized mice bearing CT26.CL25 tumors established
for 3 days with our panel of recombinant immunogens.
These immunogens were active in the absence of the T
cell growth factor IL-2, previously shown to increase the
efficacy of recombinant poxvirus-based vaccines (Bronte
et al., 1995). As shown in Fig. 4, treatment of mice with
MINIGAL, NAGAL, or BHAGAL viruses resulted in a sta-
tistically significant reduction of the number of lung me-
tastases measured at 12 days (P2 values for Experiments
1 and 2, respectively, were 0.005 and 0.004 for BIP-NA vs
MINIGAL; 0.045 and 0.007 for MNA vs NAGAL; 0.039 and
FIG. 2. Specific recognition of transfectant influenza A viruses-in-
fected cells by a b-gal-specific CTL clone. Five 3 105 CT26.WT cells/
well (24-well plate) were incubated in RPMI, 0.1% BSA, and 30 mM
HEPES at pH 6.8, and they were infected with the influenza viruses
shown at an m.o.i. of 5 for 3 h, then washed with CM and plated with
CTLX, which are specific for the b-gal epitope TPHPARIGL, at an E:T
ratio of 1. After 24 h of coincubation, cell supernatants were harvested
and assayed for GM–CSF. Results from two independent experiments
are represented. WT, influenza A/WSN/33 wild-type virus.
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0.005 for ELDKWAS vs BHAGAL). In some instances,
treated mice did not show any macroscopic evidence of
lung tumors by Day 12. The results indicate that trans-
fectant influenza A viruses expressing a single tumor
antigen determinant were able to induce a therapeutic
antitumor response in mice.
Antitumor responses elicited by transfectant H1N1
influenza viruses in mice preimmunized with an
H3N2 influenza virus
Preexisting immunity against a viral vector might pre-
vent the induction of cellular immune responses against
FIG. 3. Specific cytolytic responses induced in mice by transfectant influenza A viruses expressing the b-gal epitope TPHPARIGL. To evaluate the
function of transfectant influenza A viruses in the priming of b-gal-specific cytotoxic responses in vivo, two mice/group were injected intravenously
with 106 PFU of the influenza A virus shown on the abscissa. Three weeks later, splenocytes from immunized mice were cultured in the presence
of the Ld-restricted b-gal876-884 peptide for 6 days, then tested in a microcytotoxicity assay against CT26.WT, CT26.CL25, or CT26.WT cells loaded with
the b-gal876-884 peptide at the indicated E:T ratios. Experiment was repeated with similar results.
FIG. 4. Transfectant influenza A viruses mediate treatment of pulmonary metastases established for 3 days. Mice were inoculated intravenously
with 5 3 106 CT26.CL25 tumor cells, then vaccinated intravenously 3 days later with 106 PFU of the transfectant influenza A virus shown. The lungs
of treated mice were evaluated in a coded, blinded manner for pulmonary metastases 12 days after the tumor inoculation. The number of pulmonary
metastases that were enumerated after two independent experiments are shown for individual mice.
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its encoded antigens. Thus we investigated whether a
transfectant influenza virus expressing a tumor-associ-
ated antigen is able to elicit similarly efficient antitumor
responses in naive and in influenza-virus-immune ani-
mals. Groups of mice were first intranasally infected with
H1N1 or H3N2 influenza viruses. We used the attenuated
NA/B-NS transfectant virus and a mouse-adapted influ-
enza A/Beijing/32/92 virus as the H1N1 and H3N2 im-
munogens, respectively. The NA/B-NS virus is antigeni-
cally identical to influenza A/WSN/33 virus, but it is at-
tenuated due to the presence of specific mutations in the
promoter of one of its genes. NA/B-NS virus (103 PFU)
induces a protective immune response against influenza
virus without killing the infected mice (Muster et al.,
1991). Three weeks postinfection, all mice immunized
with the NA/B-NS virus had HI antibody titers in sera
against influenza A/WSN/33 virus but not against influ-
enza A/Beijing/32/92 virus (data not shown). Recipro-
cally, all mice immunized with influenza A/Beijing/32/92
virus had HI antibody titers in sera against influenza
A/Beijing/32/92 virus but not against influenza A/WSN/33
virus. This was expected since the hemagglutinin pro-
teins of both virus are antigenically different. H1N1-im-
mune mice bearing CT26.CL25 tumors did not respond
to treatment with a transfectant H1N1 influenza virus
(NAGAL) expressing the b-gal876-884 peptide. However,
despite the presence of cross-reactive cellular epitopes
in the internal proteins of H1N1 and H3N2 viruses, the
ability of NAGAL virus to mediate regression of estab-
lished CT26.CL25 tumors was not impaired in H3N2-
immune mice (Fig. 5).
DISCUSSION
We have shown in this communication that treatment of
tumor-bearing mice with transfectant influenza A viruses
expressing a model TAA can result in a significant reduc-
tion of the number of lung metastases measured 12 days
later. The experimental murine cancer used in these stud-
ies relies on the use of the cell line CT26.CL25. This cell line
is derived from the carcinoma cell line CT26, which was
transduced to express b-gal (Wang et al., 1995). In this
murine cancer model, the tumorigenic properties of the cell
line CT26.CL25 remain unchanged upon expression of the
model TAA b-gal. This resembles the situation in most
human tumors, which express TAA but are not able to
induce an immune response against their TAA. However, in
contrast to the mouse model that was used in our studies,
human cancers are established for longer periods of time in
the patients. In addition, most of the identified human TAA
are derived from melanoma cells, and they are also ex-
pressed in normal melanocytes. Issues of tolerance are
likely to bedevil attempts at inducing responses to self
antigens. An interesting consequence of the breaking of
tolerance in these conditions may be vitiligo, a patchy and
permanent loss of pigmentation in the skin, which has been
observed in some of our patients with melanoma who
respond positively to melanoma. Importantly, we have not
observed any ocular or aural consequences to these ap-
parent ‘‘self’’ reactivities (Rosenberg and White, 1996). Al-
though the CT26.CL25 tumor model does not address all
problems that one will encounter when treating a human
cancer, it is still very promising that influenza viruses ex-
FIG. 5. Transfectant NAGAL influenza virus (H1N1) mediates regression of established pulmonary metastases in mice that were preimmunized with
H3N2 influenza A virus. Twelve mice were inoculated intranasally with PBS, 103 PFU of influenza NA/B-NS (H1N1) virus or 103 PFU of influenza
A/Beijing/32/92 (H3N2) virus. One month after immunization, 5 3 105 CT26.CL25 tumor cells were inoculated intravenously. Three days after tumor
cell inoculation, the mice were injected intraperitoneally with 106 PFU of MNA (dark circles) or NAGAL (open squares) transfectant viruses. The
number of pulmonary metastases was determined 12 days after tumor inoculation.
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pressing a single antigenic determinant can mediate the
regression of established tumors in mice.
We have engineered three influenza virus vectors ex-
pressing the same b-gal epitope in different contexts.
Among these three transfectant viruses, BHAGAL virus,
which expresses the b-gal epitope in the context of the
HA gene, is expected to express higher levels of the
epitope than the other two viruses, MINIGAL and NA-
GAL, which express the b-gal epitope in the context of
the NA gene. This is because there are about four to five
times more copies of HA than there are NA on the
surface of an influenza A virus (Lamb and Krug, 1996). On
the other hand, the MINIGAL virus may deliver the
epitope to MHC class I molecules more efficiently due to
the use of a leader sequence in front of the epitope
(Restifo et al., 1995). Finally, one might also expect dif-
ferences in the efficiency of processing of the b-gal
epitope according to the different flanking amino acid
sequences that are present in the three viral vectors.
However, all three viruses were able to induce a thera-
peutic immune response against tumors expressing
b-gal in mice.
In clinical cancer trials at the National Cancer Institute
and elsewhere, the recombinant viral vectors that are
currently in use include E1-deleted adenoviruses and
recombinant poxviruses that encode selected human
melanoma associated antigens (MAA) (Rosenberg,
1997). It was shown previously that adenovirus- and
poxvirus-based vectors were also able to induce tumor
inhibition in experimental murine cancer models (Wang
et al., 1995; Chen et al., 1996; Bronte et al., 1997; Carroll
et al., 1997). Clinical work has recently shown that most
cancer patients have high circulating levels of neutraliz-
ing titers to the adenovirus vectors that we are using.
While humans generally do not have preexisting immu-
nity to the avian poxviruses, the vast majority of patients
have immunity to vaccinia viruses, since they have gen-
erally received the virus as children (a result of the
world-wide effort by the World-Health Organization to
eradicate smallpox). Indeed, many patients will also
have neutralizing antibodies to many different influenza
A virus strains. The presence of neutralizing antibodies
against the viral vectors in patients will more likely result
in a lower level or viral replication and of MHC class I
presentation, thus decreasing the induction of tumor
specific CD81 T cells. However, humans are susceptible
to repeated bouts of influenza because influenza viruses
can almost endlessly change the antigenic characteris-
tics of their viral coats. Tumor immunotherapists could
then choose a viral coat to which cancer patients were
not immune, for example, because the patient was not
yet born at the time the chosen viral coat type was
pandemic. The latter case, for example, could involve the
use of influenza virus vectors expressing selected TAA
(preferentially in a gene segment encoding an internal
viral protein) and bearing a viral coat from 1934 (such as
influenza A/PR/8/34 virus) to treat a population born after
that date. This strategy is supported by the experiments
shown in Fig. 5. Thus although the antigenically distinct
H3N2 and H1N1 influenza viruses share conserved
CD41 and CD81 epitopes, an H1N1 transfectant virus is
able to efficiently induce antitumor responses in mice
which were previously immunized with an H3N2 influ-
enza virus.
Another possible advantage of the use of influenza
virus vectors to express TAA is their antigenic simplicity.
Influenza A virus encodes only 10 proteins, as compared
to the 185 open reading frames of vaccinia virus, some of
which are known to encode immunosuppressive pro-
teins such as soluble, secreted homologues of cytokine
receptors. The proportion of the expressed desired anti-
gen among other viral antigens is higher for influenza
virus than for poxvirus-based vectors. Future experi-
ments are in progress to carefully compare the potency
of different vectors expressing TAA, including vaccinia
and influenza virus-based vectors.
The capacity of influenza A viruses to infect dendritic
cells and to express their genes at high levels is also an
important one. Dendritic cells are potent activators of T
lymphocyte-dependent immune responses. They have a
high density of both class I and class II MHC molecules
on their surfaces together with costimulatory molecules
like B7-1/CD80 and B7-2/CD86, as well as other T cell
activating ligands including ICAM-1/CD54. Dendritic
cells infected with influenza viruses expressing TAA ex
vivo, then reinfused, could be used to activate antitumor
T cells in vivo (Steinman, 1996). In fact, the elicitation of
potent antitumor immunity described in this manuscript
might be mediated by the infection of dendritic cells in
vivo, as shown in the case for recombinant vaccinia
virus-based immunogens (Bronte et al., 1997). Greenberg
and colleagues have recently used an ex vivo approach
in which they employ recombinant vaccinia virus infected
cells to generate antityrosinase reactivities (Yee et al.,
1996). Likewise, we have raised cytotoxic T lymphocytes
specific for MART-1/MelanA using poxvirus-infected den-
dritic cells (Kim et al., 1997). However, vaccinia viruses
are about 20-fold more antigenically complex and thus
may be more likely to elicit irrelevant reactivities than an
influenza A virus vector.
An interesting and important consideration in the de-
velopment of recombinant anticancer vaccines has to do
with boosting studies. We and others have found that
repeated administrations of the same vector to boost
cellular immune responses are usually not successful
(Murata et al., 1996; Irvine, 1997). Thus the first adminis-
tration of the vector results in the induction of neutraliz-
ing antibodies against the vector that hamper its ability to
subsequently reinfect the same patient. This could be
circumvented by combined immunizations with two dif-
ferent vectors sharing the same TAA. A very promising
protocol involves the use of an influenza virus vector to
prime an immune response against the expressed TAA,
followed by a poxvirus vector expressing the same TAA
94 RESTIFO ET AL.
for boosting. We have previously shown that this protocol
of immunization is extremely efficient in mice for the
induction of powerful specific CTL responses against
foreign malarial antigens that are expressed by the vec-
tors (Murata et al., 1996).
Safety is one major concern in the use of influenza
virus vectors in humans. Temperature-dependent host
range phenotypes exist for a variety of viruses, including
influenza A viruses (Chanock and Murphy, 1980;
Maassab et al., 1988; Crowe et al., 1995; Snyder et al.,
1990). The use of nontransmissible, attenuated cold-
adapted influenza virus vectors could provide a means to
safely administer the vector to humans. These cold-
adapted strains were obtained by propagation of the
virus at progressively lower temperatures, resulting in
the selection and accumulation of mutations responsible
for both cold-adaptation and attenuation. Alternatively,
the administration of transfectant influenza viruses by
routes different from the respiratory route could also
provide a safe way to use these vectors in humans.
Influenza A viruses productively infect the respiratory
epithelium but cause neither viral shedding nor disease
when administered by nonrespiratory routes, e.g., intra-
venously, intraperitoneally, intramuscularly, or subcuta-
neously. However, these routes of administration are
equally effective as the intranasal route in eliciting a
cellular immune response against expressed antigens
by the influenza virus vectors in mice (Murata et al.,
1996). In fact, the mouse immunizations described in this
communication were performed intravenously or intra-
peritoneally, and they resulted in both an induction of
CTLs against the model TAA and in tumor inhibition.
Finally, it is also possible to construct by reverse genet-
ics techniques stable attenuating mutations in the chi-
meric viral gene expressing the TAA. In fact, insertion of
foreign antigens into the influenza virus genome usually
results in the attenuation of the viral vector. Issues of
safety will nevertheless require further study.
In conclusion, transfectant influenza viruses express-
ing a single antigenic determinant encoded by a mini-
gene, or embedded within a structural protein, can elicit
powerful cellular immune responses and have therapeu-
tic efficacy against tumors established for 3 days in mice.
This is the first example of a negative-strand RNA virus
vector that is able to induce antitumor immune re-
sponses. To explore the use of these new vectors in
human cells in vitro, we recently engineered transfectant
influenza viruses expressing the melanoma TAA MART-1
as well as two immunogenic fragments of the gp100
molecule. To create viruses that can be used in the clinic,
we are exploring the use of strains of influenza A virus to
which there are little or no preexisting humoral immune
responses. Such viruses could be most useful in the
development of prime-boost combinations with other re-
combinant vectors. Our challenge is to identify viruses
that remain safe, immunogenic, and nontransmissible
when given to humans with cancer.
MATERIALS AND METHODS
Animals, viruses and cell lines
Six- to eight-week-old female BALB/c (H-2d) mice were
obtained from Frederick Cancer Research Center (Fred-
erick, MD). CT26 is an N-nitroso-N-methylurethrane-
induced BALB/c (H-2d) undifferentiated colon carcinoma.
The cloning of this tumor cell line to produce CT26.WT
and the subsequent transduction with lacZ and subclon-
ing to generate CT26.CL25, which stably expresses
b-gal, has been described previously (Wang et al., 1995).
These cell lines were maintained in RPMI 1640, 10% heat
inactivated FCS (Biofluids, Rockville, MD), 0.03% L-
glutamine, 100 mg/ml streptomycin, 100 mg/ml penicillin,
and 50 mg/ml gentamicin sulfate (NIH Media Center). In
addition, 400 or 800 mg/ml G418 (GIBCO, Grand Island,
NY) was added to the maintenance media of the
CT26.CL25 cells. Madin-Darby bovine kidney (MDBK)
cells were used for growing wild-type influenza
A/WSN/33 (H1N1) virus and for rescuing and growing
H1N1 transfectant influenza viruses. Attenuated trans-
fectant NA/B-NS influenza virus (H1N1) was previously
described (Muster et al., 1991). MDBK cells were main-
tained in reinforced minimal essential medium contain-
ing 10% heat inactivated FCS (GIBCO). Influenza A/Bei-
jing/32/92 virus (H3N2) was adapted to mice by passag-
ing seven times in the lungs of BALB/c mice. Mouse
adapted influenza A/Beijing/32/92 virus was grown in
10-day-old embryonated chicken eggs.
Construction and characterization of transfectant
influenza A viruses
The construction of the transfectant influenza viruses
BIP-NA, MNA, and ELDKWAS, which were used in con-
trol experiments, has been described (Rodrigues et al.,
1994; Garcı´a-Sastre et al., 1994; Muster et al., 1994).
Transfectant viruses which express the Ld-restricted
b-gal epitope TPHPARIGL were obtained by RNP-trans-
fection as previously described (Garcı´a-Sastre and
Palese, 1993). These viruses contain one RNA segment
that is derived from genetically engineered plasmid
cDNA encoding the neuraminidase (NA) or hemaggluti-
nin (HA) genes of influenza A/WSN/33 virus. One virus,
called MINIGAL, encodes the amino-acid sequence
MRYMILGLLALAAVCSAATPHPARIGL from a minicistron
followed by a mammalian internal ribosomal entry site
(IRES) element just upstream of the NA open reading
frame. Amino-acid residues in front of the b-gal epitope
TPHPARIGL are derived from the leader peptide of the
E3/19K protein (Restifo et al., 1995). A control virus, BIP-
NA, contains the same IRES sequences upstream of the
NA open reading frame but lacks the b-gal minicistron
(Garcı´a-Sastre et al., 1994). The second transfectant vi-
rus, NAGAL, encodes the amino-acid sequence TPH-
PARIGL inserted in the stalk region of the NA protein. The
third transfectant influenza virus, BHAGAL, encodes the
95TRANSFECTANT INFLUENZA A VIRUS VACCINES
same b-gal epitope inserted into the antigenic site B of
the viral HA protein. MNA and ELDKWAS viruses, which
contain irrelevant epitope insertions in the same context
as NAGAL and BHAGAL viruses, respectively, were used
as controls. Transfectant viruses were plaque purified
three times in MDBK cells, and their identities were
subsequently confirmed by RT–PCR and sequencing of
gene regions containing the engineered foreign se-
quences (Garcı´a-Sastre et al., 1994).
Peptides
The synthetic peptide TPHPARIGL was synthesized by
Peptide Technologies (Washington, DC) to a purity of
greater than 99% as assessed by HPLC and amino-acid
analysis. This peptide represents the naturally pro-
cessed H-2 Ld-restricted epitope spanning amino acids
876–884 of b-gal (Gavin et al., 1993; Wang et al., 1995).
51Chromium release assays
Six-hour 51Cr release assays were performed as
previously described (Restifo et al., 1993). Briefly, 2
[times 106 target cells were incubated with 200 mCi
Na51CrO4(
51Cr) for 90 min. Peptide-pulsed CT26.WT
cells were incubated with 1 mg/ml of synthetic peptide
during labeling. Target cells were then mixed with
effector cells for 6 h at the effector to target (E:T) ratios
indicated. The amount of 51Cr released was deter-
mined by g-counting, and the percentage of specific
lysis was calculated from triplicate samples as fol-
lows: [(experimental cpm-spontaneous cpm)/(maximal
cpm 2 spontaneous cpm)] 3 100.
In vitro stimulation of b-gal-specific cytotoxic T cells
CT26.WT cells, 105/well in 96-well U-bottom plates
(Costar) were incubated in complete medium (RPMI, 0.1%
BSA, and 30 mM HEPES at pH 6.8) and infected with the
influenza viruses shown at an m.o.i. of 20 for 3 h. CTLX,
were then added at an E:T of 1. Note that CTLX, is a clone
specific for a peptide with the sequence TPHPARIGL
corresponding to the naturally processed epitope from
b-gal (spanning amino acids 876–884) and presented by
the H-2 Ld molecule. After 24 h of coincubation, super-
natants were harvested and assayed for GM–CSF using
a commercially available ELISA kit (R&D, Minneapolis,
MN). GM–CSF levels were used as a measure of CD81
T cell reactivity.
In vivo experiments
Active treatment studies involved BALB/c mice inocu-
lated intravenously with 5 3 105 CT26.CL25 cells. Three
days later, mice were randomized and then inoculated
intravenously or intraperitoneally with 106 PFU of the
indicated transfectant or wild-type influenza virus.
Twelve days after tumor injection, mice were ear tagged,
randomized again, and sacrificed. Lung metastases
were enumerated in a blinded fashion by an investigator
with no knowledge of the experimental groups. Preim-
munizations of mice were done as follows: mice were
inoculated intranasally with 103 PFU of influenza NA/
B-NS virus or of mouse-adapted influenza A/Beijing/
32/92 virus. Three weeks after immunization, sera were
collected, and the presence of antibodies against influ-
enza A/WSN/33 and A/Beijing/32/92 viruses was deter-
mined using a hemagglutination inhibition (HI) assay.
Statistical analysis
Data concerning to the number of lung metastases do
not follow a normal distribution (since all lungs that
contain .250 metastases were deemed too numerous to
count) and thus were analyzed using the nonparametric
two-tailed Kruskal-Wallis test. All statistical values ex-
pressed are P2 (two-tailed P) values.
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